|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvedBy
|
gptkb:FDA
1999
|
|
gptkbp:ATCCode
|
J05AH02
|
|
gptkbp:CASNumber
|
gptkb:139504-50-0
|
|
gptkbp:contraindication
|
hypersensitivity to oseltamivir
|
|
gptkbp:hasInChIKey
|
RZVAJINKPMORJF-QMMMGPOBSA-N
|
|
gptkbp:hasMolecularFormula
|
C16H28N2O4
|
|
gptkbp:hasSMILES
|
CCOC(=O)C1=C(C[C@@H](NC(=O)C)[C@@H](N)C1)OC(C)CC
|
|
gptkbp:hasUNII
|
R7T0KZ6CMO
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
139504-50-0
|
|
gptkbp:isAdministeredAs
|
oral medication
|
|
gptkbp:IUPACName
|
ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:listedOn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:marketedAs
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
neuraminidase inhibitor
|
|
gptkbp:meltingPoint
|
205-206 °C
|
|
gptkbp:molecularWeight
|
312.40 g/mol
|
|
gptkbp:name
|
gptkb:Oseltamivir
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prodrugOf
|
oseltamivir carboxylate
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL123
58560
65028
DB00198
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
headache
|
|
gptkbp:synonym
|
gptkb:GS-4104
gptkb:Tamiflu
|
|
gptkbp:target
|
gptkb:influenza_virus
|
|
gptkbp:usedFor
|
antiviral drug
prevention of influenza
treatment of influenza A
treatment of influenza B
|
|
gptkbp:wasPatentedIn
|
1996
|
|
gptkbp:bfsParent
|
gptkb:DM1_(emtansine)
|
|
gptkbp:bfsLayer
|
7
|